林业发展局核准新的前列腺癌药物Darolutumatide,显示在推迟癌症发展方面有重大好处。 FDA approves new prostate cancer drug, darolutamide, showing significant benefits in delaying cancer progression.

根据最近的一项研究,FDA已批准达罗胺用于治疗转移性割敏感前列腺癌, 显示其在延缓癌症进展和改善生活质量方面具有显著的益处. The FDA has approved darolutamide for treating metastatic castration-sensitive prostate cancer, showing significant benefits in delaying cancer progression and improving quality of life, according to a recent study. 该药物,如果与苯丙胺脱氧疗法结合使用,则通过将癌症增加或死亡的风险降低46%,优于安慰剂的效绩。 The drug, when combined with androgen deprivation therapy, outperformed placebo by reducing the risk of cancer progression or death by 46%. 它还延缓了疼痛进展,改善了病人的整体福祉。 It also delayed pain progression and improved overall well-being in patients.